Spots Global Cancer Trial Database for Safety Study of Oral Vinorelbine in Subjects With Non-Hematologic Malignancies
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Safety Study of Oral Vinorelbine in Subjects With Non-Hematologic Malignancies
Official Title: A Phase 1 Study of the Safety, Pharmacokinetics, and Biological Activity of Metronomic Dosing With Orally Administered Vinorelbine Tablets in Subjects With Non-Hematologic Malignancies For Which There Are No Currently Accepted Therapies
Study ID: NCT00641160
Conditions
Study Description
Brief Summary: The purpose of this study is to determine the safety of oral administration of vinorelbine once daily for at least 7 days. The study will be conducted in subjects with a non-hematologic malignancy for which there are no currently accepted therapies.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Texas Oncology PA; Sammons Cancer Center, Dallas, Texas, United States
Contact Details
Name: George Tidmarsh, MD, PhD
Affiliation: Metronome Therapeutics
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
